Cantor Fitzgerald Reiterates Overweight on Ocular Therapeutix (OCUL) Following 1Q

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/22/2026

1. META
2. TSLA
3. IBM
4. TXN
5. MRNA
6. SAP
7. CSX
8. LRCX
9. MRK
10. LVS

Go back to Cantor Fitzgerald Reiterates Overweight on Ocular Therapeutix (OCUL) Following 1Q

Ocular Therapeutix™ Reports First Quarter 2018 Financial Results and Business Update

May 8, 2018 4:01 PM EDT

Targeting DEXTENZA NDA Resubmission in the Second Quarter of 2018

BEDFORD, Mass.--(BUSINESS WIRE)-- Ocular Therapeutix, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced financial results for the first quarter ended March 31, 2018 and provided a business update.

We entered 2018 with an exciting set of opportunities that include a number of regulatory and clinical milestones, said Antony Mattessich, President and Chief Executive Officer. With the right strategy, objectives and leadership in... More